 "Dr. Reddy's inks pact with Singapore firm to sell Trastuzumab biosimilar")
: Prestige BioPharma Ltd, a Singapore-based firm and Dr. Reddy's Laboratories Ltd., on Thursday announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialisation of the former's proposed Trastuzumab biosimilar in select countries in Latin America and Southeast Asia.
Prestige BioPharma's Trastuzumab (HD201) is a proposed biosimilar to Roche's Herceptin and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer, a regulatory filing from the Indian drug maker said.
Trastuzumab targets human epidermal growth factor 2 (HER2). In some types of cancer cells, HER2 is overexpressed and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells, it said.
Under the partnership, Prestige BioPharma will be responsible for sustainable commercial supply of HD201 from its manufacturing facilities in Osong, South Korea, while Dr. Reddy's will be responsible for local registrations, marketing and sales in the licensed territories.
Lisa S Park, CEO of Prestige BioPharma, commented: "We are delighted to establish a partnership with Dr. Reddy's for key Latin American and Southeast Asian markets. Dr. Reddy's is the ideal partner to commercialise our lead biosimilar in these territories. With this collaboration, we look forward to further strengthening the value of our biosimilar programs in global markets."
M V Ramana, CEO Branded Markets (India & Emerging Markets), Dr. Reddy's, said: "In keeping with our purpose of accelerating access to affordable and innovative medicines, we are happy to bring this life-saving drug to patients in need. Our partnership with Prestige BioPharma will help us combine their established expertise in the area of biosimilars with our commercial strengths and growth ambition in these markets. This is in line with our stated intention to create a portfolio of oncology products and expand our biosimilar offerings in Emerging Markets.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)